EP0152281A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Transdermal formulation of nicardipine hydrochloride
Assignee: Astellas Pharma Inc
•
Filing: 1985-02-07
•
Granted: —
•
Expires: 2005-02-07
Abstract
Abstract A transdermal formulation of nicardipine hydrochloride which comprises [a] a transdermal formulation base compounded with [b] nicardipine hydrochloride dissolved or suspended in a liquid containing a urea and at least one compound selected from propylene glycol, monohydric alcohols having 2 to 4 carbon atoms, lactic acid, thioglycol, middle chain fatty acid glycerides and sorbitan middle chain fatty acid esters. Such formulations give improved percutaneous absorption of the nicardipine hydrochloride. <??>Inclusion in the formulation of crystallizing inhibitor for nicardipine hydrochloride can improve the stability of the formulation.
Inventors
- 👤 Yutaka Konno
- 👤 Hiroitsu Kawata
- 👤 Masayoshi Aruga
- 👤 Takashi Sonobe
- 👤 Mitsuo Mitomi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 08:51
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/12; A61K47/14; A61K47/16; A61K47/18; A61K47/20; A61K47/26; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
53 words
A medicament composition suitable for transdermal applications, the composition comprising nicardipine hydrochloride dissolved or suspended in a liquid containing a urea and at least one compound selected from propylene glycol, monohydric alcohols having 2 to 4 carbon atoms, lactic acid, thioglycol, middle chain fatty acid glycerides and sorbitan middle chain fatty acid esters.
Claim 2
Dependent Claim
53 words
A medicament composition suitable for transdermal applications, the composition comprising nicardipine hydrochloride dissolved or suspended in a liquid containing a urea and at least one compound selected from propylene glycol, monohydric alcohols having 2 to 4 carbon atoms, lactic acid, thioglycol, middle chain fatty acid glycerides and sorbitan middle chain fatty acid esters.
Claim 3
Dependent Claim
12 words
A composition according to claim 1 wherein the said liquid includes ethanol.
Claim 4
Dependent Claim
31 words
A composition according to claim 1 or 2 wherein the middle chain fatty acid glyceride component is selected from mono- and di-glycerides of fatty acids having 6 to 12 carbon atoms.
Claim 5
Dependent Claim
33 words
A composition according to claim 1,2 or 3 wherein the sorbitan middle chain fatty acid ester component is selected from mono- and di-esters of fatty acids having from 6 to 12 carbon atoms.
Claim 6
Dependent Claim
13 words
A composition according to any preceding claim wherein the said liquid includes urea.
Claim 7
Dependent Claim
13 words
A composition according to any preceding claim wherein the said liquid includes water.
Claim 8
Dependent Claim
21 words
A transdermanl formulation of nicardipine hydrochloride which comprises a composition according to any preceding claim compounded with a transdermal formulation base.
Claim 9
Dependent Claim
16 words
A composition or formulation according to any preceding claim containing a crystallization inhibitor for nicardipine hydrochloride.
Claim 10
Dependent Claim
31 words
A composition or formulation according to claim 8 wherein the crystallization inhibitor is at least one compound selected from propylene glycol didecanoate, neopentyl glycol, di-2-ethylhexanoate, and polyoxy- ethyelne-hardened castor oil derivatives.
Claim 11
Dependent Claim
21 words
A composition or formulation according to any preceding claim on a substrate carrier layer, e.g. of fabric, paper, plastics or metal.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.